Breakthrough Treatments for Metabolic Syndrome

Learn More
Learn more about Diamedica

About Diamedica

DiaMedica Inc. is a publicly traded, clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases.

About Diamedica
Learn more about Diamedica

Product Pipeline

DiaMedica’s lead clinical stage product, DM199, is a recombinant human protein to treat diabetes and associated complications. DM204 is a novel monoclonal antibody for the treatment of type 2 diabetes.

View Pipeline ›